Intellectual Asset Management Recognizes Foley Attorneys in 2020 Patent 1000 Guide
May 1, 2020
Patent 1000 – The World’s Leading Patent Professionals
Intellectual Asset Management (IAM) has recognized 16 Foley attorneys in the 9th edition of its Patent 1000 – The World’s Leading Patent Professionals guide. Additionally, the firm was recognized for offices and practices, including the District of Columbia (prosecution), Boston (prosecution and litigation) Detroit, Milwaukee and Tokyo (litigation).
The Foley attorneys recognized include:
- Scott Anderson, prosecution
- Courtenay Brinckerhoff, prosecution
- Jeffrey Costakos, litigation
- Etsuo Doi, transactions
- Jeanne Gills, litigation
- Jeffrey Gundersen, prosecution
- John Lanza, prosecution
- Matthew Lowrie, litigation
- Stephen Maebius, post-grant proceedings, prosecution, transactions
- Christopher McKenna, prosecution
- George Quillin, post-grant proceedings, prosecution
- Michele Simkin, prosecution
- Gary Solomon, prosecution
- Eric Sophir, prosecution
-
Marcus Sprow, prosecution
- Joseph Ziebert, prosecution
The Patent 1000 – The World’s Leading Patent Professionals guide is compiled by a team of researchers from IAM magazine based on more than 1,800 interviews with private practice and in-house professionals regarding the full range of patent services.
People
Related News
June 22, 2026
In the News
Aaron Maguregui Authors Article on Building Scalable, Secure AI Strategies
Foley & Lardner LLP partner Aaron Maguregui authored the HealthTech article, “A Digital Health CEO’s Guide to Fast, Secure Scaling of AI,” offering guidance to digital health leaders on artificial intelligence scaling.
June 5, 2026
In the News
Jeffrey Blease Featured Across the Media for Litigation Department Chair Appointment
Foley & Lardner LLP partner Jeffrey Blease is featured across legal media for his recent appointment as chair of the firm's national litigation department.
June 5, 2026
In the News
David Rosen Discusses SCOTUS Ruling on Generic Drug Labeling
Foley & Lardner LLP partner David Rosen is quoted across the media for his analysis of the U.S. Supreme Court case Hikma Pharmaceuticals v. Amarin Pharma.